Fundraising Fox

ENB Therapeutics

New York, US · Founded 2018 · Delaware corporation · 6 employees on LinkedIn · 2 known investors

ENB Therapeutics develops small molecules targeting the endothelin B receptor (ETBR) in the tumor microenvironment to treat drug-resistant cancers by restoring immune cell infiltration and promoting tertiary lymphoid organ formation. Its preclinical therapies target cancers including melanoma, glioblastoma, squamous cell carcinoma, bladder cancer, and ovarian cancer.

BiotechHealthtech

Founders & leadership

ENB Therapeutics was founded in 2018 by Sumayah Jamal and Robert Schneider.

SJ
Sumayah JamalPresident, Co-founder & Chief Scientific Officer
RS
Robert SchneiderCo-founder & Chair of Scientific Advisory Board
SH
Sandy HarmChief Operating Officer
FM
Fumitaka MoriNamed on SEC filing
AS
Albert SokolNamed on SEC filing

Board

BSBarbara Schilberg
Barbara SchilbergBoard directorAdvisor & Former CEO at BioAdvance

Investors · 2

BioAdvanceConshohocken · $500K – $1.5M
Remiges Ventures, Inc.Seattle

Reported raises · per SEC filings

Form D private placements

$9.6M disclosed across 3 rounds · 2018–2023

▶$225KraisedOct 2023 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Sumayah JamalExecutive Officer, Director
  • Barbara SchilbergDirector
  • Stuart HwangDirector
  • Walter OlesiakDirector
  • Albert SokolExecutive Officer
Offering amount
$1M
Amount sold
$225K
First sale
Sep 2023
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.3MraisedJan 2021 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Barbara SchilbergDirector
  • Albert SokolExecutive Officer
  • Fumitaka MoriDirector
  • Sumayah JamalExecutive Officer, Director
Offering amount
$2.6M
Amount sold
$1.3M
First sale
Jan 2021
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$8.1MraisedFeb 2020 · 17 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Barbara SchilbergDirector
  • Fumitaka MoriDirector
  • Sumayah JamalExecutive Officer, Director
  • Albert SokolExecutive Officer
Offering amount
$9.1M
Amount sold
$8.1M
First sale
Sep 2018
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Bioworld9 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with ENB Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

ENB Therapeutics to present at the 2023 BIO CEO & Investor and Immuno-Oncology 360o Conferencesbusinesswire.com · Jan 2023ENB Therapeutics Closes Series A Round of Funding - ANY Seed Fundanyseedfund.com · Sep 2018

Frequently asked questions

What does ENB Therapeutics do?
ENB Therapeutics develops small molecules targeting the endothelin B receptor (ETBR) in the tumor microenvironment to treat drug-resistant cancers by restoring immune cell infiltration and promoting tertiary lymphoid organ formation. Its preclinical therapies target cancers including melanoma, glioblastoma, squamous cell carcinoma, bladder cancer, and ovarian cancer.
Who founded ENB Therapeutics?
ENB Therapeutics was founded by Sumayah Jamal, Robert Schneider in 2018.
Who are ENB Therapeutics's investors?
ENB Therapeutics's investors include BioAdvance, Remiges Ventures, Inc..
How much funding has ENB Therapeutics raised?
ENB Therapeutics has disclosed $9.6M raised across 3 rounds.
Where is ENB Therapeutics headquartered?
ENB Therapeutics is headquartered in New York, US.